By Sam Whitehouse, CEO, LightOx
When we first started building LightOx, we didn’t set out with a grand plan to transform cancer care. We were simply following the science — and asking better questions.
What if we could treat mouth cancers earlier, before they became life-altering? What if treatment could be local, light-activated, and precise, reducing harm instead of compounding it? And what if the same technology could scale across conditions that have long been under-prioritised, from aggressive oral cancers to infected wounds?
Since then, we’ve built a company focused on one of the most overlooked, underserved – and, frankly, underfunded – spaces in oncology: oral cancer. We’ve made tough calls, pivoted when we needed to, and never lost sight of the reason we’re here: to create therapies that work, and deliver meaningful outcomes that matter to patients.
Here are five of the most important lessons that have shaped that journey.
1. Follow the science, even when it leads you somewhere unexpected
The molecules that became the foundation of LightOx weren’t designed for oncology. But they had an interesting property: they could be activated by light. That crucial detail sparked a bigger idea of developing this chemistry into a drug that works only where and when you need it.
Mouth cancer was a natural focus. It’s surface-level. It’s aggressive. It has high recurrence. And because surgery is often the only option, patients face life-altering outcomes including loss of functions such as speech or eating, disfigurement, even social stigma. In turn, this has resulted in very few patient advocates, leaving oral cancer with a huge unmet need.
We saw a space where our platform could make a real difference. A localised treatment for early-stage disease. Something simple, effective and potentially transformative. That’s the kind of opportunity you only see if you’re willing to look sideways and ask, “What else could this do?”
This same philosophy is exactly why we have evolved into wound care as a second application. We had a platform capable of local, light-activated therapy. Why should that be limited to oncology? It’s a different application, but the same basic principle of treating only what you need to, as simply as possible.
2. Building a biotech is about more than the science
If you’re spinning out a company from academia, you must understand that your corporate structure will either raise money or repel it. I’ve seen brilliant science die in the valley of investor due diligence because the spinout terms were a legal nightmare.
At LightOx, we spent time upfront making sure our structure was investable. That included redefining IP ownership, cleaning up shareholder agreements, and making sure we had a compelling licensing model. It’s boring work, but nothing else happens without it.
Investors need to see clarity and capability from the start — not just in the lab, but in the boardroom. We’ve built LightOx to scale, and that starts by treating the business infrastructure with as much care as the science.
3. Be willing to adapt
LightOx didn’t start with a revolutionary cancer treatment, we started by selling fluorescent probes. This was a way to generate early revenue, demonstrate technical credibility, and keep momentum while we shaped our long-term strategy.
Those early sales weren’t the end goal, they were proof that we could operate commercially. But as we moved forward, the focus shifted. Our platform showed strong potential in oncology, and we prioritised drug development. We now have a lead candidate heading towards first-in-human trials — a major milestone that redefines what LightOx is.
We now have a scalable platform and the ability to deliver targeted therapies for previously intractable conditions. That shift didn’t happen overnight. It happened by making smart, deliberate decisions at every stage.
4. Build something you believe in
Building a biotech isn’t easy. There are days when progress is slow, funding is uncertain, and the hurdles feel endless. What keeps you going is believing in what you’re building.
At LightOx, we’ve made a deliberate choice to work on problems that matter. Oral cancer is the sixth most common cancer globally, yet it is often overlooked. Our technology offers the potential to intervene earlier, more precisely, and in a way that preserves quality of life. These outcomes are deeply important for patients, as well as valuable for the company and our investors.
We’ve also expanded into wound care, where chronic infections and antimicrobial resistance create an enormous global healthcare burden. It’s a space where innovation has lagged for decades, and where scalable, low-barrier solutions are urgently needed.
Choosing to focus on these areas has given us a clear sense of purpose and the motivation to keep moving forward despite the many hurdles. And in a world where most biotech companies cluster around the same indications, standing out isn’t just strategic — it’s essential.
5. Create the company you’d want to work in
The most valuable thing we’ve built at LightOx isn’t just the platform — it’s the team. People who’ve taken PhD research into the clinic. People who’ve grown their skills, shaped the culture, and stayed because they believe in what we’re doing.
This kind of belief really matters in the inherently unstable world of startups. You’re asking people to take a leap, to join you in uncertainty, and your culture needs to be strong enough to carry that. Biotech is built by people. Respect them, grow them, and they’ll build something bigger than you imagined.
That thinking should extend beyond your own walls. We’re proud to be part of a growing biotech community in the North East of England that’s collaborative, ambitious, and ready to lead. But talent can’t grow without investment.
We’ve seen firsthand how access to capital shapes not just companies, but entire ecosystems. That’s why we make time to support emerging founders, share what we’ve learned, and advocate for deeper networks in underfunded regions.
What’s next for LightOx?
Right now, we are entering the most pivotal phase of our journey. Our lead oncology candidate is preparing to enter clinical trials. Our wound care programme is currently in preclinical development. And we’re proving that our platform can reshape how we treat some of the world’s toughest health challenges.
But we can’t do it alone. We’re looking for partners who see what we see: a platform with global relevance, a team with resilience, and a future where patients have access to a better quality of life.
If you’d like to learn more about our journey, get in touch: sam.whitehouse@lightox.co.uk
